Zum Inhalt springen Zur Suche springen

News-Detail

Effective Use of BCMA-Targeting Bispecific T-Cell-Engaging Antibody in Treatment Refractory LRP4-positive Myasthenia Gravis.
Stefanie Schreiber et al., Mol Ther. 2025

Stefanie Schreiber, Marwa Al-Dubai, Stefan Vielhaber, Lora Lefterova, Sascha Dietrich, Tobias Ruck, Sven Meuth, Denise Walther, Dimitrios Mougiakakos.

Effective Use of BCMA-Targeting Bispecific T-Cell-Engaging Antibody in Treatment Refractory LRP4-positive Myasthenia Gravis.

Mol Ther. 2025 Sep 3;33(9):4130-4134. doi: 10.1016/j.ymthe.2025.06.029. Epub 2025 Jun 17. PubMed ID: 40534130

 

Further Information:

DOI: 10.1016/j.ymthe.2025.06.029

Sven Meuth

Kategorie/n: NND-Publikationen